Hydrocortisone butyrate
Brand names: Locoid
Hydrocortisone butyrate is a potent topical corticosteroid used for steroid-responsive inflammatory skin conditions such as eczema and dermatitis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It binds glucocorticoid receptors in skin cells to produce anti-inflammatory, immunosuppressive and vasoconstrictive effects; despite the hydrocortisone name, the butyrate ester confers potent activity.
Prescribing in practice
- Note that, unlike plain hydrocortisone, hydrocortisone butyrate is a potent steroid, so apply the lowest effective amount for the shortest time and take particular care on the face and flexures to limit atrophy and systemic absorption.
- Reserve for inflammatory dermatoses requiring a potent agent and step down as control is achieved.
- Do not apply to untreated bacterial, fungal or viral skin infection.
Monitoring
No routine laboratory monitoring is required; review for treatment response and local corticosteroid adverse effects such as skin thinning.
Counselling the patient
- This is a strong steroid despite its name; apply thinly to affected areas only and not as a general moisturiser.
- Avoid the face and skin folds unless specifically directed and do not use on infected skin.
- Continue regular emollients alongside treatment.
Evidence & guidelines
Topical corticosteroids are central to NICE eczema management, with potent agents such as hydrocortisone butyrate selected by disease severity and site.
Reference: NICE CG57; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD